44 completed, 28 recruiting, 16 active not recruiting, 7 terminated. 36 Phase 3, 19 Phase 2, 18 Phase 4, 15 Phase 1, 4 Not applicable.
Follow guselkumab: new trials by email Literature Review of guselkumab trials Research Report on guselkumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon Adalimumab, Guselkumab, SDL-001 - Healthy Subjects | Phase 1 | Not yet recruiting | Surmount Services, Inc. | 18 | 2026-09-15 | 2026-08-26 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-10-05 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis Guselkumab - Ulcerative Colitis (Disorder), Guselkumab | Recruiting | Second Affiliated Hospital of Wenzhou Medical University | 97 | 2026-07-31 | 2026-10-20 | |
| Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Guselkumab - Crohn Disease (CD), Intensification | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 210 | 2026-06-18 | 2026-06-30 |
| A Phase 3 Clinical Study of QL2106 Injection QL2106 injection, Tremfya® - Plaque Psoriasis | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 318 | 2026-05-27 | 2026-10-19 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-78934804, Guselkumab - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 644 | 2026-05-23 | 2026-10-13 |
| A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease JNJ-78934804, Guselkumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 460 | 2026-05-22 | 2026-10-14 |
| Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis Guselkumab - Spondyloarthritis, Inflammatory Bowel Diseases | Not yet recruiting | NYU Langone Health | 75 | 2026-05-20 | 2026-05-22 | |
| Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease Guselkumab (GUS), Risankizumab (RISA) - Psoriasis, Psoriasis Arthritis | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-03-09 | |
| GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Guselkumab, Diet - Pouchitis | Phase 4 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 20 | 2026-04-23 | 2026-05-05 |
| A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Guselkumab, Risankizumab - Crohn Disease | Phase 3 | Recruiting | Janssen Research & Development, LLC | 530 | 2026-04-21 | 2026-09-25 |
| An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection Guselkumab - Crohn's Disease (CD) | Not yet recruiting | Shanghai 10th People's Hospital | 88 | 2026-04-15 | 2026-04-14 | |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease Guselkumab (GUS), Ustekinumab (UST) - CD - Crohn's Disease, Stricture; Bowel | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2026-03-01 | 2026-03-02 | |
| Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) Guselkumab (Tremfya) - Inflammatory Bowel Disease (IBD), Crohn Disease (CD) | Recruiting | TIDHI Innovation Inc. | 200 | 2026-01-29 | 2026-08-31 | |
| A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD) guselkumab (GUS), JAK inhibitors (such as upadacitinib/tofacitinib) - Inflamatory Bowel Disease | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 80 | 2026-01-07 | 2026-03-23 | |
| A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) Guselkumab (GUS) - Crohn Disease | Phase 4 | Recruiting | Xian-Janssen Pharmaceutical Ltd. | 78 | 2025-12-30 | 2026-09-25 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy Guselkumab Prefilled Syringe [Tremfya] - Psoriasis (PsO), PsA (Psoriatic Arthritis) | Withdrawn | University of California, San Diego | 2025-11-30 | 2026-02-23 |
Showing 20 of 104. Sign in to see all of them.
Psoriasis (33) · Arthritis, Psoriatic (18) · Crohn Disease (18) · Colitis, Ulcerative (9) · Inflammatory Bowel Diseases (5) · Arthritis, Juvenile (3) · Hidradenitis Suppurativa (3) · Adenomatous Polyposis Coli (2) · Arthritis, Rheumatoid (2) · Giant Cell Arteritis (2) · Skin Diseases (2) · Spondylarthritis (2) · Autoimmune Diseases (1) · Celiac Disease (1) · Congenital Abnormalities (1)
Janssen Research & Development, LLC (43) · Janssen Pharmaceutical K.K. (7) · Janssen-Cilag Ltd. (4) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · University of California, San Diego (4) · NYU Langone Health (3) · University of California, San Francisco (3) · Janssen Pharmaceutica N.V., Belgium (2) · Oregon Health and Science University (2) · Alimentiv Inc. (1) · Anne Chang (1) · Caja Costarricense de Seguro Social (1) · Centocor, Inc. (1) · Centre Hospitalier Universitaire de Nice (1) · Centre for Human Drug Research, Netherlands (1)
United States (62) · Germany (33) · Poland (33) · Spain (31) · Canada (30) · France (25) · Italy (25) · Australia (21) · Belgium (21) · China (20) · Hungary (18) · Japan (18) · United Kingdom (18) · Czechia (17) · Netherlands (17)
Raymond Cho, MD, PhD (2) · Alex G Ortega-Loayza, MD, MCR (1) · Alexis Ogdie-Beatty, MD, MSCE (1) · Anne Chang, MD (1) · Christina Chambers, PhD, MPH (1) · Christopher Moller (1) · David Hudesman, MD (1) · Elke de Jong, MD, PhD (1)
PMID 37906417, PMID 36642439, PMID 41396391, PMID 29799960, PMID 30417277, PMID 33822898, PMID 33934076, PMID 34011674, PMID 34105767, PMID 34261541, PMID 35296534, PMID 35766811, PMID 37713133, PMID 37750995, PMID 38485863, PMID 38488975, PMID 38765190, PMID 39261446, PMID 39320583, PMID 39706209, PMID 41152645, PMID 41326161, PMID 26154787, PMID 28057360, PMID 28057361, PMID 28087506, PMID 29417135, PMID 29893222, PMID 30485400, PMID 30887876, PMID 31207232, PMID 31268476, PMID 31402114, PMID 31421033, PMID 32178765, PMID 32178766, PMID 32407591, PMID 32665433, PMID 32880909, PMID 32910434, PMID 33043600, PMID 33359090, PMID 34518264, PMID 34614172, PMID 34656148, PMID 34819273, PMID 35134323, PMID 35279805, PMID 35352313, PMID 35768650
2023 (14), 2018 (6), 2016 (5), 2014 (4), 2019 (4), 2017 (1), 2025 (1)